Journal article
Raising the stakes: Loss of efflux pump regulation decreases meropenem susceptibility in burkholderia pseudomallei
DS Sarovich, JR Webb, MC Pitman, LT Viberg, M Mayo, RW Baird, JM Robson, BJ Currie, EP Price
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2018
DOI: 10.1093/cid/ciy069
Abstract
Background Burkholderia pseudomallei, the causative agent of the high-mortality disease melioidosis, is a gram-negative bacterium that is naturally resistant to many antibiotics. There is no vaccine for melioidosis, and effective eradication is reliant on biphasic and prolonged antibiotic administration. The carbapenem drug meropenem is the current gold standard option for treating severe melioidosis. Intrinsic B. pseudomallei resistance toward meropenem has not yet been documented; however, resistance could conceivably develop over the course of infection, leading to prolonged sepsis and treatment failure. Methods We examined our 30-year clinical collection of melioidosis cases to identify ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council (grant numbers 1046812, 1098337, and 1131932); Advance Queensland (grant number AQRF13016-17RD2 to D.S.S.); Australian Federation of Graduate Women (Barbara Hale Fellowship to J.R.W.); and the University of the Sunshine Coast (to E.P.P.).